| . "Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression.." Am J Hum Genet. 2011;89(2):277-88. Pub Med |
| . "fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies.." BMC Bioinformatics. 2019;20(1):333. Pub Med |
| . "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.." Lancet Oncol. 2017;18(6):732-742. Pub Med |
| . "Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases.." J Clin Oncol. 2016;34(9):945-52. Pub Med |
| . "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy.." Breast Cancer Res. 2017;19(1):18. Pub Med |
| . "Latent class model characterization of neighborhood socioeconomic status.." Cancer Causes Control. 2016;27(3):445-52. Pub Med |
| . "Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas.." Cancer Causes Control. 2019;30(1):31-39. Pub Med |
| . "Generation of a transcriptional radiation exposure signature in human blood using long-read nanopore sequencing.." Radiat Res. 2020;193(2):143-154. Pub Med |
| . "Toxicity related to radiotherapy dose and targeting strategy: A pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer.." J Thorac Oncol. 2019;14(2):298-303. Pub Med |
| . "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy.." Technol Cancer Res Treat. 2019;18():1533033819849073. Pub Med |
| . "Risk calculators are useful but....." J Thorac Cardiovasc Surg. 2016;151(3):706-707. Pub Med |
| . "Toxicity related to radiotherapy dose and targeting strategy: A pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer.." J Thorac Oncol. 2019;14(2):298-303. Pub Med |
| . "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy.." Technol Cancer Res Treat. 2019;18():1533033819849073. Pub Med |
| . "Toxicity related to radiotherapy dose and targeting strategy: A pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer.." J Thorac Oncol. 2019;14(2):298-303. Pub Med |
| . "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy.." Technol Cancer Res Treat. 2019;18():1533033819849073. Pub Med |
| . "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy.." Technol Cancer Res Treat. 2019;18():1533033819849073. Pub Med |
| . "Racial differences in diffusion of intensity-modulated radiation therapy for localized prostate cancer.." Am J Mens Health. 2016;10(5):399-407. Pub Med |
| . "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy.." Technol Cancer Res Treat. 2019;18():1533033819849073. Pub Med |
| . "Sequential multiple assignment randomization trials with enrichment design.." Biometrics. 2017;73(2):378-390. Pub Med |
| . "Power and sample size calculations for SNP association studies with censored time-to-event outcomes.." Genet Epidemiol. 2012;36(6):538-48. Pub Med |
| . "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.." J Biopharm Stat. 2015;25(1):66-88. Pub Med |
| . "Sample size calculation for cluster randomization trials with a time-to-event endpoint.." Stat Med. 2020;39(25):3608-3623. Pub Med |
| . "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.." Ann Oncol. 2019;30(4):542-550. Pub Med |
| . "Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.." Biometrics. 2012;68(2):578-86. Pub Med |
| . "Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data.." Biometrics. 2018;74(4):1180-1192. Pub Med |
| . "Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme.." Biometrics. 2013;69(3):714-23. Pub Med |
| . "Bayesian influence measures for joint models for longitudinal and survival data.." Biometrics. 2012;68(3):954-64. Pub Med |
| . "Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.." Biostatistics. 2011;12(2):258-69. Pub Med |
| . "Characterizing expected benefits of biomarkers in treatment selection.." Biostatistics. 2015;16(2):383-99. Pub Med |
| . "Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.." Breast Cancer Res Treat. 2017;166(1):167-177. Pub Med |
| . "Genomewide meta-analysis validates a role for S1PR1 in microtubule targeting agent-induced sensory peripheral neuropathy.." Clin Pharmacol Ther. 2020;108(3):625-634. Pub Med |
| . "LIBERTI: A SMART study in plastic surgery.." Clin Trials. 2018;15(3):286-293. Pub Med |
| . "Network meta-analysis of randomized clinical trials: reporting the proper summaries.." Clin Trials. 2014;11(2):246-62. Pub Med |
| . "Bayesian clinical trial design using Markov models with applications to autoimmune disease.." Contemp Clin Trials. 2017;63():73-83. Pub Med |
| . "Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results.." J Biopharm Stat. 2018;28(4):633-644. Pub Med |
| . "Randomized phase II clinical trials.." J Biopharm Stat. 2014;24(4):802-16. Pub Med |
| . "Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.." J Biopharm Stat. 2016;26(2):269-79. Pub Med |
| . "Optimal estimation for regression models on τ-year survival probability.." J Biopharm Stat. 2015;25(3):539-47. Pub Med |
| . "Medical records-based postmarketing safety evaluation of rare events with uncertain status.." J Biopharm Stat. 2013;23(1):201-12. Pub Med |
| . "Optimal two-stage log-rank test for randomized phase II clinical trials.." J Biopharm Stat. 2017;27(4):639-658. Pub Med |
| . "On enrichment strategies for biomarker stratified clinical trials.." J Biopharm Stat. 2018;28(2):292-308. Pub Med |
| . "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?." J Biopharm Stat. 2017;27(3):457-476. Pub Med |
| . "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.." J Biopharm Stat. 2017;27(6):933-944. Pub Med |
| . "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.." J Biopharm Stat. 2015;25(1):66-88. Pub Med |
| . "Biomarker threshold adaptive designs for survival endpoints.." J Biopharm Stat. 2018;28(6):1038-1054. Pub Med |
| . "A framework for understanding cancer comparative effectiveness research data needs.." J Clin Epidemiol. 2012;65(11):1150-8. Pub Med |
| . "Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: Exploratory analysis of the REMAGUS02 trial.." J Clin Oncol. 2019;37(8):624-635. Pub Med |
| . "Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies.." J Clin Oncol. 2017;35(25):2885-2892. Pub Med |
| . "Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.." J Natl Cancer Inst. 2012;104(3):211-27. Pub Med |
| . "Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer.." J Thorac Oncol. 2015;10(7):1099-106. Pub Med |
